

**Table 4: Risk Factors for  $\geq 2$  Lines Improvement of Macular Edema-Induced Reduction of Visual Acuity**

		N	Estimated Proportion Resolved (95% Confidence Interval)	Unadjusted		Adjusted**	
				6-Month	Hazard Ratio	p-value	Hazard Ratio
All	All	1510	51.9% (49.0% - 54.6%)	n/a			
Age at uveitis diagnosis	<26	424	50.5% (45.7% - 54.9%)	1.00	0.71	1.00	0.57
	26-45	589	53.3% (49.2% - 57.2%)	1.08 (0.93 - 1.26)		1.10 (0.94 - 1.29)	
	46-65	366	50.6% (45.5% - 55.2%)	1.00 (0.84 - 1.19)		0.98 (0.81 - 1.19)	
	>65	131	53.1% (44.4% - 60.4%)	1.08 (0.84 - 1.36)		1.05 (0.81 - 1.36)	
Sex	Male	496	50.4% (45.9% - 54.6%)	1.00	0.40	1.00	0.48
	Female	1014	52.6% (49.3% - 55.6%)	1.06 (0.93 - 1.21)		1.06 (0.92 - 1.21)	
Race category	White	1159	52.3% (49.2% - 55.2%)	1.00	0.46	1.00	0.56
	Black	200	47.7% (40.5% - 54.0%)	0.88 (0.72 - 1.05)		1.01 (0.83 - 1.24)	
	Hispanic	72	57.4% (44.4% - 67.3%)	1.15 (0.86 - 1.51)		1.23 (0.91 - 1.63)	
	Other	79	51.3% (39.6% - 60.8%)	0.97 (0.72 - 1.28)		1.01 (0.74 - 1.34)	
Smoking	Never	759	54.2% (50.3% - 57.8%)	1.00	0.02	1.00	0.75
	Past	188	50.3% (44.2% - 55.8%)	0.90 (0.74 - 1.08)		1.02 (0.84 - 1.24)	
	Current	382	52.7% (47.7% - 57.2%)	0.96 (0.83 - 1.11)		0.97 (0.83 - 1.13)	
	Unknown	181	42.7% (35.9% - 48.8%)	0.71 (0.58 - 0.87)		0.88 (0.70 - 1.10)	
Laterality of uveitis	Unilateral	189	56.7% (48.8% - 63.3%)	1.00	0.15	1.00	>0.99
	Bilateral	1321	51.3% (48.3% - 54.1%)	0.86 (0.72 - 1.04)		1.00 (0.83 - 1.22)	
Visual Acuity at Diagnosis of ME	Better than 20/200	1122	48.9% (45.8% - 51.8%)	1.00	<0.001	1.00	<0.001
	20/200 or worse	388	60.9% (55.6% - 65.6%)	1.40 (1.22 - 1.60)		1.46 (1.26 - 1.68)	
Site of Uveitis	Anterior	424	60.7% (55.6% - 65.2%)	1.00	<0.001	1.00	0.02
	Intermediate	533	50.4% (46.3% - 54.2%)	0.75 (0.65 - 0.87)		0.83 (0.70 - 1.00)	
	Posterior	285	49.6% (43.6% - 55.0%)	0.74 (0.61 - 0.88)		0.76 (0.63 - 0.93)	
	Panuveitis	268	44.0% (38.4% - 49.2%)	0.62 (0.51 - 0.75)		0.73 (0.59 - 0.89)	
Overall Activity at ME Diagnosis	Inactive	436	46.5% (41.9% - 50.6%)	1.00	<0.001	1.00	<0.01
	Slightly active	211	41.0% (35.2% - 46.4%)	0.85 (0.68 - 1.04)		0.89 (0.70 - 1.13)	
	Active	863	57.6% (54.0% - 60.9%)	1.37 (1.20 - 1.58)		1.27 (1.08 - 1.50)	

**Table 4: Risk Factors for  $\geq 2$  Lines Improvement of Macular Edema-Induced Reduction of Visual Acuity**

			<b>Estimated Proportion Resolved (95% Confidence Interval)</b>	<b>Unadjusted</b>		<b>Adjusted**</b>	
		<b>N</b>	<b>6-Month</b>	<b>Hazard Ratio</b>	<b>p-value</b>	<b>Hazard Ratio</b>	<b>p-value</b>
Change in Anterior Chamber Cells	$\geq 2$ steps better (or to 0)	*	65.2% (60.5% - 69.3%)	1.59 (1.39 - 1.83)	<0.001 <0.001†	1.50 (1.29 - 1.74)	<0.001 <0.001†
	1 step better	*	59.4% (49.9% - 67.1%)	1.36 (1.06 - 1.72)		1.31 (1.00 - 1.68)	
	No change	*	48.5% (44.9% - 51.8%)	1.00		1.00	
	1 step worse	*	38.5% (30.9% - 45.3%)	0.73 (0.57 - 0.93)		0.77 (0.60 - 0.97)	
	$\geq 2$ steps worse (or to 4+)	*	35.0% (25.3% - 43.5%)	0.65 (0.46 - 0.89)		0.64 (0.45 - 0.87)	
Change in Vitreous Cells	$\geq 2$ steps better (or to 0)	*	60.7% (55.8% - 65.1%)	1.34 (1.16 - 1.55)	<0.001 <0.001†	1.24 (1.06 - 1.45)	<0.01 <0.001†
	1 step better	*	55.0% (47.1% - 61.7%)	1.15 (0.93 - 1.40)		1.30 (1.04 - 1.61)	
	No change	*	50.2% (46.5% - 53.6%)	1.00		1.00	
	1 step worse	*	41.8% (33.0% - 49.4%)	0.78 (0.59 - 1.01)		0.90 (0.68 - 1.18)	
	$\geq 2$ steps worse (or to 4+)	*	38.5% (29.2% - 46.7%)	0.70 (0.51 - 0.93)		0.73 (0.53 - 0.98)	
Change in Vitreous Haze	$\geq 2$ steps better (or to 0)	*	57.6% (51.0% - 63.2%)	1.15 (0.96 - 1.37)	<0.001 <0.001†	1.17 (0.97 - 1.40)	<0.01 <0.001†
	1 step better	*	58.1% (38.7% - 71.4%)	1.17 (0.70 - 1.81)		1.21 (0.73 - 1.89)	
	No change	*	52.6% (49.4% - 55.5%)	1.00		1.00	
	1 step worse	*	13.5% (0.0% - 29.9%)	0.20 (0.03 - 0.60)		0.22 (0.04 - 0.68)	
	$\geq 2$ steps worse (or to 4+)	*	33.4% (23.8% - 41.7%)	0.54 (0.39 - 0.74)		0.62 (0.44 - 0.85)	
Snowballs	No	*	51.8% (48.9% - 54.5%)	1.00	0.64	1.00	0.88
	Yes	*	54.6% (41.7% - 64.6%)	1.08 (0.78 - 1.45)		1.03 (0.74 - 1.40)	
Snowballs at ME Diagnosis	No	1389	51.2% (48.3% - 54.0%)	1.00	0.04	1.00	0.09
	Yes	118	60.2% (50.9% - 67.8%)	1.28 (1.02 - 1.59)		1.23 (0.96 - 1.55)	
Snowbanking	No	*	52.4% (49.5% - 55.2%)	1.00	0.03	1.00	0.049
	Yes	*	38.3% (26.0% - 48.6%)	0.65 (0.43 - 0.94)		0.67 (0.43 - 0.99)	
Snowbanking at ME Diagnosis	No	1412	51.9% (48.9% - 54.6%)	1.00	0.87	1.00	0.89
	Yes	95	52.6% (43.4% - 60.3%)	1.02 (0.79 - 1.30)		1.02 (0.77 - 1.33)	
HLA-B27	No	1419	51.4% (48.5% - 54.1%)	1.00	0.12	1.00	0.51
	Yes	91	60.2% (47.1% - 70.1%)	1.28 (0.99 - 1.62)		1.10 (0.85 - 1.42)	
Cataract Surgery prior to ME	No	1114	53.3% (50.1% - 56.3%)	1.00	0.08	1.00	0.07
	Aphakic	135	44.2% (36.1% - 51.4%)	0.77 (0.61 - 0.96)		0.75 (0.58 - 0.95)	
	Pseudophakic	261	49.9% (44.3% - 55.0%)	0.91 (0.77 - 1.07)		0.88 (0.74 - 1.05)	
Glaucoma Surgery Prior to ME	No	1457	52.1% (49.2% - 54.8%)	1.00	0.45	1.00	0.84
	Yes	53	46.6% (31.2% - 58.6%)	0.85 (0.59 - 1.19)		0.96 (0.65 - 1.36)	

**Table 4: Risk Factors for ≥2 Lines Improvement of Macular Edema-Induced Reduction of Visual Acuity**

			<b>Estimated Proportion Resolved (95% Confidence Interval)</b>	<b>Unadjusted</b>		<b>Adjusted**</b>	
		<b>N</b>	<b>6-Month</b>	<b>Hazard Ratio</b>	<b>p-value</b>	<b>Hazard Ratio</b>	<b>p-value</b>
Pars Plana Vitrectomy Prior to ME	No	1350	52.4% (49.4% - 55.2%)	1.00	0.21	1.00	0.73
	Yes	160	47.8% (40.6% - 54.2%)	0.88 (0.71 - 1.07)		0.96 (0.75 - 1.22)	
Posterior Synechiae	No	*	52.4% (49.4% - 55.2%)	1.00	0.29	1.00	0.01
	Yes	*	49.0% (42.7% - 54.6%)	0.91 (0.76 - 1.08)		0.78 (0.64 - 0.94)	
Peripheral Anterior Synechiae	No	*	51.9% (49.1% - 54.6%)	1.00	0.53	1.00	0.78
	Yes	*	46.2% (25.1% - 61.3%)	0.85 (0.47 - 1.38)		0.93 (0.52 - 1.52)	
Epiretinal Membrane	No	*	52.9% (49.6% - 55.9%)	1.00	0.19	1.00	0.49
	Yes	*	49.6% (45.1% - 53.7%)	0.91 (0.80 - 1.04)		0.95 (0.83 - 1.09)	
Hypotony (<5 mmHg)	No	*	52.2% (49.3% - 54.9%)	1.00	<0.01	1.00	<0.01
	Yes	*	14.6% (0.0% - 27.3%)	0.21 (0.07 - 0.50)		0.21 (0.06 - 0.49)	
Ocular hypertension (>21 mmHg)	No	*	51.2% (48.2% - 54.0%)	1.00	0.11	1.00	0.32
	Yes	*	57.3% (49.3% - 64.0%)	1.19 (0.97 - 1.44)		1.11 (0.90 - 1.36)	
Topical prostaglandin analogues	No	*	52.1% (49.2% - 54.8%)	1.00	0.34	1.00	0.66
	Yes	*	40.8% (14.8% - 58.9%)	0.71 (0.32 - 1.33)		0.85 (0.39 - 1.61)	
Topical carbonic anhydrase inhibitors	No	*	52.3% (49.3% - 55.1%)	1.00	0.20	1.00	0.47
	Yes	*	47.2% (39.2% - 54.1%)	0.86 (0.66 - 1.11)		0.92 (0.70 - 1.19)	
Oral non-steroidal anti-inflammatory drugs	No	*	51.7% (48.8% - 54.5%)	1.00	0.33	1.00	0.74
	Yes	*	55.9% (46.6% - 63.6%)	1.12 (0.88 - 1.41)		1.04 (0.81 - 1.31)	
Oral acetazolamide	No	*	51.8% (48.9% - 54.5%)	1.00	0.29	1.00	0.27
	Yes	*	59.0% (43.2% - 70.4%)	1.22 (0.86 - 1.67)		1.22 (0.86 - 1.67)	

\* Time updated covariates vary in their number at risk over time, and therefore cannot be represented by a single number.

\*\* Adjusted smoking, primary uveitis diagnosis, visual acuity at diagnosis of ME, uveitis category, overall activity at ME diagnosis, change in anterior chamber cells, HLA-B27 status, cataract surgery prior to ME, hypotony (<5 mmHg), and ocular hypertension (>21 mmHg). Time-varying inflammatory activity markers were not adjusted by change in anterior chamber cells (see Methods for explanation).

† Test of linear trend across categories.

Abbreviations: n/a = not applicable; ME = macular edema.